BioCentury
ARTICLE | Company News

Metra sales and marketing update

June 17, 1996 7:00 AM UTC

MTRA revised downward its product revenue estimates for the fiscal year ending June 30. Revenues will be $1.4-$1.7 million for the quarter and $6.2-$6.6 million for the year. The company also said it expects product revenues for fiscal 1997 to range from $12-$14 million. MTRA's lead product, Pyrilinks-D, was approved in the U.S. last December. ...